Trastuzumab Deruxtecan Safety, Prophylaxis, and Dose Modification in Breast Cancer

Authored by Eric Kowalchyk, published on 2026-11-06 19:48:56.0

The algorithm is broadly aligned with current FDA-approved breast cancer indications and the May 2026 ENHERTU prescribing information. Its ILD, hematologic, cardiac, infusion-reaction, antiemetic, and dose-reduction pathways are largely label-concordant. Several details require qualification, particularly mandatory corticosteroids for Grade 1 ILD, LVEF reassessment criteria, and restriction of the radiation-pneumonitis pathway to the adjuvant setting.

  1. Assess Pulmonary History, Imaging, LVEF, CBC, Organ Function, and Pregnancy
    The label directly requires baseline CBC, LVEF, and pregnancy assessment and provides hepatic and renal cautions. Pulmonary history and baseline imaging are supported by multidisciplinary ILD guidance.
    • Active ILD, Pregnancy, or Unacceptable Cardiac/Organ Risk?
      • Defer T-DXd and Resolve Risk or Select Alternative Therapy
      • Select Breast Cancer Setting and T-DXd Indication
        • Neoadjuvant Stage II–III HER2+: T-DXd Then THP
          DESTINY-Breast11 and the May 2026 FDA approval directly support four cycles of neoadjuvant T-DXd followed by four cycles of THP for HER2-positive stage II-III disease.
          • Give Antiemetic Prophylaxis and Educate on Respiratory Symptoms
            Current labeling classifies T-DXd as highly emetogenic and requires prophylactic antiemetics. It also instructs patients to report cough, dyspnea, fever, or other new respiratory symptoms immediately.
            • Screen Symptoms and Review CBC, Organ Function, and LVEF
              The label requires CBC before every dose, regular LVEF assessment as clinically indicated, and prompt investigation of respiratory symptoms. Organ function should be followed according to baseline impairment and clinical toxicity.
              • Identify the Management-Determining Toxicity
                • No Management-Determining Toxicity: Continue Treatment
                • Hold T-DXd and Obtain Chest CT and Pulmonary Evaluation
                  For suspected ILD, current labeling calls for treatment interruption, radiographic evaluation and consideration of pulmonology consultation.
                  • Classify Pulmonary Toxicity Grade and Etiology
                    Management depends on CTCAE grade and whether findings represent drug-induced ILD, radiation pneumonitis, infection, progression, or another cause.
                    • Grade 1 ILD: hold T-DXd, consider corticosteroids, and reimage
                      Grade 1 ILD: immediate management Asymptomatic radiographic ILD/pneumonitis suspected during T-DXd treatment. Hold T-DXd until complete resolution to Grade 0. Evaluate alternative causes, including infection, tumor progression and radiation-related lung injury. Review chest imaging and consider pulmonology consultation. Consider systemic corticosteroids promptly (e.g., prednisolone ≥0.5 mg/kg/day or equivalent), based on clinical assessment. Monitoring Monitor for new cough, dyspnea, fever or oxygen desaturation. Arrange clinical and radiographic reassessment to document resolution before restarting T-DXd. Individualize the timing of follow-up imaging according to clinical findings. T-DXd restart criteria Resolution to Grade 0 within ≤28 days of onset: resume at the same dose. Resolution to Grade 0 after >28 days: resume at one dose level lower. For breast cancer, the first dose reduction is from 5.4 to 4.4 mg/kg. Stop rule If symptomatic drug-induced ILD/pneumonitis (Grade ≥2) develops, permanently discontinue T-DXd and promptly initiate systemic corticosteroid treatment.
                      • Grade 1 ILD Recovered Promptly: Resume Same Dose
                      • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                        These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                    • Grade ≥2 Drug-Induced ILD: Permanently Discontinue T-DXd
                      This is a boxed-warning management requirement: permanently discontinue T-DXd and promptly initiate systemic corticosteroids for symptomatic Grade 2 or higher ILD.
                    • Grade 2 Radiation Pneumonitis: Hold; Resume Same Dose After Resolution
                      In the adjuvant HER2-positive breast cancer setting, distinguish radiotherapy-related pneumonitis from T-DXd–induced ILD. Evaluation: Review symptoms, oxygenation, chest CT findings, radiation fields, timing of radiotherapy, and alternative causes, including infection. Suspected T-DXd–induced ILD: For Grade 1, interrupt T-DXd until complete resolution and follow the ILD dose-modification pathway. For Grade 2 or higher, permanently discontinue T-DXd and promptly initiate corticosteroids. Only radiotherapy-related pneumonitis suspected: For Grade 2, consider interrupting T-DXd. For Grade 3 or higher, permanently discontinue T-DXd. Reassess clinical recovery and diagnosis before considering treatment resumption. This radiotherapy-specific exception applies only in the adjuvant setting.
                    • Grade ≥3 Radiation Pneumonitis: Permanently Discontinue T-DXd
                    • Treat Alternative Cause; Continue T-DXd Once ILD Is Excluded
                • Grade Neutropenia or Thrombocytopenia
                  Check CBC before each T-DXd dose and as clinically indicated. Grade 3 neutropenia (ANC 0.5 to less than 1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 4 neutropenia (ANC less than 0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Assess fever or suspected infection urgently and fFebrile neutropenia: ANC <1.0 x 10^9/L with temperature >38.3°C or ≥38°C sustained for more than 1 hour. Interrupt T-DXd. Urgently evaluate and treat suspected infection according to febrile neutropenia protocols. After resolution, resume T-DXd at one dose level lower. Do not re-escalate. Do not re-escalate T-DXd after dose reduction.
                  • Grade 3 Cytopenia: Hold Until Recovery; Resume Same Dose
                    Grade 3 neutropenia (ANC 0.5 to <1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 3 thrombocytopenia (platelets 25 to <50 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at the same dose. Check CBC and confirm hematologic recovery before the next infusion. Evaluate fever, infection, or clinically significant bleeding urgently.
                  • Grade 4 or Febrile Cytopenia: Hold; Resume at Reduced Dose
                    Grade 4 neutropenia (ANC <0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Febrile neutropenia (ANC <1.0 x 10^9/L with fever >38.3°C or ≥38°C sustained for more than 1 hour): Interrupt T-DXd. Urgently evaluate and treat infection according to institutional protocols. Resume at one dose level lower after resolution. Grade 4 thrombocytopenia (platelets <25 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at one dose level lower. Breast cancer dose levels: 5.4 → 4.4 → 3.2 mg/kg. Do not re-escalate after dose reduction.
                    • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                      These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                • Classify LVEF Change and Heart Failure Symptoms
                  The label stratifies management by absolute LVEF, change from baseline, confirmation on repeat testing and presence of symptomatic CHF.
                  • Mild LVEF Change: Continue T-DXd and Monitor
                    LVEF >45% with an absolute decline <10 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF >45% with an absolute decline of 10–20 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF 40–45% with an absolute decline <10 percentage points: Continue T-DXd and repeat LVEF within 3 weeks. Other LVEF declines or symptomatic heart failure: Follow the appropriate interruption or discontinuation pathway.Permanently discontinue T-DXd.
                  • Significant Asymptomatic Decline: Hold and Repeat LVEF
                    LVEF 40–45% with an absolute decrease of 10–20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF recovers to within 10% of baseline, resume T-DXd at the same dose. Otherwise, permanently discontinue. LVEF <40% or an absolute decrease >20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF <40% or the >20% decrease is confirmed, permanently discontinue T-DXd.
                    • LVEF Recovery Criteria Met: Continue Treatment
                      Following interruption for LVEF 40–45% with a 10–20% absolute decrease from baseline, resume T-DXd at the same dose only if LVEF recovers to within 10% of baseline. Continue regular LVEF monitoring and reassess any new cardiac symptoms. If recovery criteria are not met, permanently discontinue T-DXd.
                    • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                      Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                  • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                    Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                • Determine Outcome After Other Toxicity Management
                  • Controlled Other Toxicity: Continue or Resume Same Dose
                  • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                    These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                  • Severe Infusion Reaction: Permanently Discontinue T-DXd
        • Residual HER2+ Disease: Adjuvant T-DXd for 14 Cycles
          DESTINY-Breast05 established postneoadjuvant T-DXd as superior to T-DM1 for high-risk residual invasive HER2-positive disease, and FDA approved treatment for up to 14 cycles.
          • Give Antiemetic Prophylaxis and Educate on Respiratory Symptoms
            Current labeling classifies T-DXd as highly emetogenic and requires prophylactic antiemetics. It also instructs patients to report cough, dyspnea, fever, or other new respiratory symptoms immediately.
            • Screen Symptoms and Review CBC, Organ Function, and LVEF
              The label requires CBC before every dose, regular LVEF assessment as clinically indicated, and prompt investigation of respiratory symptoms. Organ function should be followed according to baseline impairment and clinical toxicity.
              • Identify the Management-Determining Toxicity
                • No Management-Determining Toxicity: Continue Treatment
                • Hold T-DXd and Obtain Chest CT and Pulmonary Evaluation
                  For suspected ILD, current labeling calls for treatment interruption, radiographic evaluation and consideration of pulmonology consultation.
                  • Classify Pulmonary Toxicity Grade and Etiology
                    Management depends on CTCAE grade and whether findings represent drug-induced ILD, radiation pneumonitis, infection, progression, or another cause.
                    • Grade 1 ILD: hold T-DXd, consider corticosteroids, and reimage
                      Grade 1 ILD: immediate management Asymptomatic radiographic ILD/pneumonitis suspected during T-DXd treatment. Hold T-DXd until complete resolution to Grade 0. Evaluate alternative causes, including infection, tumor progression and radiation-related lung injury. Review chest imaging and consider pulmonology consultation. Consider systemic corticosteroids promptly (e.g., prednisolone ≥0.5 mg/kg/day or equivalent), based on clinical assessment. Monitoring Monitor for new cough, dyspnea, fever or oxygen desaturation. Arrange clinical and radiographic reassessment to document resolution before restarting T-DXd. Individualize the timing of follow-up imaging according to clinical findings. T-DXd restart criteria Resolution to Grade 0 within ≤28 days of onset: resume at the same dose. Resolution to Grade 0 after >28 days: resume at one dose level lower. For breast cancer, the first dose reduction is from 5.4 to 4.4 mg/kg. Stop rule If symptomatic drug-induced ILD/pneumonitis (Grade ≥2) develops, permanently discontinue T-DXd and promptly initiate systemic corticosteroid treatment.
                      • Grade 1 ILD Recovered Promptly: Resume Same Dose
                      • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                        These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                    • Grade ≥2 Drug-Induced ILD: Permanently Discontinue T-DXd
                      This is a boxed-warning management requirement: permanently discontinue T-DXd and promptly initiate systemic corticosteroids for symptomatic Grade 2 or higher ILD.
                    • Grade 2 Radiation Pneumonitis: Hold; Resume Same Dose After Resolution
                      In the adjuvant HER2-positive breast cancer setting, distinguish radiotherapy-related pneumonitis from T-DXd–induced ILD. Evaluation: Review symptoms, oxygenation, chest CT findings, radiation fields, timing of radiotherapy, and alternative causes, including infection. Suspected T-DXd–induced ILD: For Grade 1, interrupt T-DXd until complete resolution and follow the ILD dose-modification pathway. For Grade 2 or higher, permanently discontinue T-DXd and promptly initiate corticosteroids. Only radiotherapy-related pneumonitis suspected: For Grade 2, consider interrupting T-DXd. For Grade 3 or higher, permanently discontinue T-DXd. Reassess clinical recovery and diagnosis before considering treatment resumption. This radiotherapy-specific exception applies only in the adjuvant setting.
                    • Grade ≥3 Radiation Pneumonitis: Permanently Discontinue T-DXd
                    • Treat Alternative Cause; Continue T-DXd Once ILD Is Excluded
                • Grade Neutropenia or Thrombocytopenia
                  Check CBC before each T-DXd dose and as clinically indicated. Grade 3 neutropenia (ANC 0.5 to less than 1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 4 neutropenia (ANC less than 0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Assess fever or suspected infection urgently and fFebrile neutropenia: ANC <1.0 x 10^9/L with temperature >38.3°C or ≥38°C sustained for more than 1 hour. Interrupt T-DXd. Urgently evaluate and treat suspected infection according to febrile neutropenia protocols. After resolution, resume T-DXd at one dose level lower. Do not re-escalate. Do not re-escalate T-DXd after dose reduction.
                  • Grade 3 Cytopenia: Hold Until Recovery; Resume Same Dose
                    Grade 3 neutropenia (ANC 0.5 to <1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 3 thrombocytopenia (platelets 25 to <50 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at the same dose. Check CBC and confirm hematologic recovery before the next infusion. Evaluate fever, infection, or clinically significant bleeding urgently.
                  • Grade 4 or Febrile Cytopenia: Hold; Resume at Reduced Dose
                    Grade 4 neutropenia (ANC <0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Febrile neutropenia (ANC <1.0 x 10^9/L with fever >38.3°C or ≥38°C sustained for more than 1 hour): Interrupt T-DXd. Urgently evaluate and treat infection according to institutional protocols. Resume at one dose level lower after resolution. Grade 4 thrombocytopenia (platelets <25 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at one dose level lower. Breast cancer dose levels: 5.4 → 4.4 → 3.2 mg/kg. Do not re-escalate after dose reduction.
                    • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                      These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                • Classify LVEF Change and Heart Failure Symptoms
                  The label stratifies management by absolute LVEF, change from baseline, confirmation on repeat testing and presence of symptomatic CHF.
                  • Mild LVEF Change: Continue T-DXd and Monitor
                    LVEF >45% with an absolute decline <10 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF >45% with an absolute decline of 10–20 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF 40–45% with an absolute decline <10 percentage points: Continue T-DXd and repeat LVEF within 3 weeks. Other LVEF declines or symptomatic heart failure: Follow the appropriate interruption or discontinuation pathway.Permanently discontinue T-DXd.
                  • Significant Asymptomatic Decline: Hold and Repeat LVEF
                    LVEF 40–45% with an absolute decrease of 10–20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF recovers to within 10% of baseline, resume T-DXd at the same dose. Otherwise, permanently discontinue. LVEF <40% or an absolute decrease >20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF <40% or the >20% decrease is confirmed, permanently discontinue T-DXd.
                    • LVEF Recovery Criteria Met: Continue Treatment
                      Following interruption for LVEF 40–45% with a 10–20% absolute decrease from baseline, resume T-DXd at the same dose only if LVEF recovers to within 10% of baseline. Continue regular LVEF monitoring and reassess any new cardiac symptoms. If recovery criteria are not met, permanently discontinue T-DXd.
                    • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                      Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                  • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                    Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                • Determine Outcome After Other Toxicity Management
                  • Controlled Other Toxicity: Continue or Resume Same Dose
                  • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                    These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                  • Severe Infusion Reaction: Permanently Discontinue T-DXd
        • First-Line HER2+ Metastatic: T-DXd Plus Pertuzumab
          DESTINY-Breast09 demonstrated superior progression-free survival over taxane-trastuzumab-pertuzumab, leading to FDA approval of first-line T-DXd plus pertuzumab.
          • Give Antiemetic Prophylaxis and Educate on Respiratory Symptoms
            Current labeling classifies T-DXd as highly emetogenic and requires prophylactic antiemetics. It also instructs patients to report cough, dyspnea, fever, or other new respiratory symptoms immediately.
            • Screen Symptoms and Review CBC, Organ Function, and LVEF
              The label requires CBC before every dose, regular LVEF assessment as clinically indicated, and prompt investigation of respiratory symptoms. Organ function should be followed according to baseline impairment and clinical toxicity.
              • Identify the Management-Determining Toxicity
                • No Management-Determining Toxicity: Continue Treatment
                • Hold T-DXd and Obtain Chest CT and Pulmonary Evaluation
                  For suspected ILD, current labeling calls for treatment interruption, radiographic evaluation and consideration of pulmonology consultation.
                  • Classify Pulmonary Toxicity Grade and Etiology
                    Management depends on CTCAE grade and whether findings represent drug-induced ILD, radiation pneumonitis, infection, progression, or another cause.
                    • Grade 1 ILD: hold T-DXd, consider corticosteroids, and reimage
                      Grade 1 ILD: immediate management Asymptomatic radiographic ILD/pneumonitis suspected during T-DXd treatment. Hold T-DXd until complete resolution to Grade 0. Evaluate alternative causes, including infection, tumor progression and radiation-related lung injury. Review chest imaging and consider pulmonology consultation. Consider systemic corticosteroids promptly (e.g., prednisolone ≥0.5 mg/kg/day or equivalent), based on clinical assessment. Monitoring Monitor for new cough, dyspnea, fever or oxygen desaturation. Arrange clinical and radiographic reassessment to document resolution before restarting T-DXd. Individualize the timing of follow-up imaging according to clinical findings. T-DXd restart criteria Resolution to Grade 0 within ≤28 days of onset: resume at the same dose. Resolution to Grade 0 after >28 days: resume at one dose level lower. For breast cancer, the first dose reduction is from 5.4 to 4.4 mg/kg. Stop rule If symptomatic drug-induced ILD/pneumonitis (Grade ≥2) develops, permanently discontinue T-DXd and promptly initiate systemic corticosteroid treatment.
                      • Grade 1 ILD Recovered Promptly: Resume Same Dose
                      • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                        These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                    • Grade ≥2 Drug-Induced ILD: Permanently Discontinue T-DXd
                      This is a boxed-warning management requirement: permanently discontinue T-DXd and promptly initiate systemic corticosteroids for symptomatic Grade 2 or higher ILD.
                    • Grade 2 Radiation Pneumonitis: Hold; Resume Same Dose After Resolution
                      In the adjuvant HER2-positive breast cancer setting, distinguish radiotherapy-related pneumonitis from T-DXd–induced ILD. Evaluation: Review symptoms, oxygenation, chest CT findings, radiation fields, timing of radiotherapy, and alternative causes, including infection. Suspected T-DXd–induced ILD: For Grade 1, interrupt T-DXd until complete resolution and follow the ILD dose-modification pathway. For Grade 2 or higher, permanently discontinue T-DXd and promptly initiate corticosteroids. Only radiotherapy-related pneumonitis suspected: For Grade 2, consider interrupting T-DXd. For Grade 3 or higher, permanently discontinue T-DXd. Reassess clinical recovery and diagnosis before considering treatment resumption. This radiotherapy-specific exception applies only in the adjuvant setting.
                    • Grade ≥3 Radiation Pneumonitis: Permanently Discontinue T-DXd
                    • Treat Alternative Cause; Continue T-DXd Once ILD Is Excluded
                • Grade Neutropenia or Thrombocytopenia
                  Check CBC before each T-DXd dose and as clinically indicated. Grade 3 neutropenia (ANC 0.5 to less than 1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 4 neutropenia (ANC less than 0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Assess fever or suspected infection urgently and fFebrile neutropenia: ANC <1.0 x 10^9/L with temperature >38.3°C or ≥38°C sustained for more than 1 hour. Interrupt T-DXd. Urgently evaluate and treat suspected infection according to febrile neutropenia protocols. After resolution, resume T-DXd at one dose level lower. Do not re-escalate. Do not re-escalate T-DXd after dose reduction.
                  • Grade 3 Cytopenia: Hold Until Recovery; Resume Same Dose
                    Grade 3 neutropenia (ANC 0.5 to <1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 3 thrombocytopenia (platelets 25 to <50 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at the same dose. Check CBC and confirm hematologic recovery before the next infusion. Evaluate fever, infection, or clinically significant bleeding urgently.
                  • Grade 4 or Febrile Cytopenia: Hold; Resume at Reduced Dose
                    Grade 4 neutropenia (ANC <0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Febrile neutropenia (ANC <1.0 x 10^9/L with fever >38.3°C or ≥38°C sustained for more than 1 hour): Interrupt T-DXd. Urgently evaluate and treat infection according to institutional protocols. Resume at one dose level lower after resolution. Grade 4 thrombocytopenia (platelets <25 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at one dose level lower. Breast cancer dose levels: 5.4 → 4.4 → 3.2 mg/kg. Do not re-escalate after dose reduction.
                    • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                      These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                • Classify LVEF Change and Heart Failure Symptoms
                  The label stratifies management by absolute LVEF, change from baseline, confirmation on repeat testing and presence of symptomatic CHF.
                  • Mild LVEF Change: Continue T-DXd and Monitor
                    LVEF >45% with an absolute decline <10 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF >45% with an absolute decline of 10–20 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF 40–45% with an absolute decline <10 percentage points: Continue T-DXd and repeat LVEF within 3 weeks. Other LVEF declines or symptomatic heart failure: Follow the appropriate interruption or discontinuation pathway.Permanently discontinue T-DXd.
                  • Significant Asymptomatic Decline: Hold and Repeat LVEF
                    LVEF 40–45% with an absolute decrease of 10–20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF recovers to within 10% of baseline, resume T-DXd at the same dose. Otherwise, permanently discontinue. LVEF <40% or an absolute decrease >20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF <40% or the >20% decrease is confirmed, permanently discontinue T-DXd.
                    • LVEF Recovery Criteria Met: Continue Treatment
                      Following interruption for LVEF 40–45% with a 10–20% absolute decrease from baseline, resume T-DXd at the same dose only if LVEF recovers to within 10% of baseline. Continue regular LVEF monitoring and reassess any new cardiac symptoms. If recovery criteria are not met, permanently discontinue T-DXd.
                    • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                      Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                  • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                    Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                • Determine Outcome After Other Toxicity Management
                  • Controlled Other Toxicity: Continue or Resume Same Dose
                  • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                    These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                  • Severe Infusion Reaction: Permanently Discontinue T-DXd
        • Prior Anti-HER2 or Early Relapse: T-DXd Monotherapy
          The indication is supported by FDA labeling, while DESTINY-Breast03 provides pivotal randomized evidence after trastuzumab and taxane exposure.
          • Give Antiemetic Prophylaxis and Educate on Respiratory Symptoms
            Current labeling classifies T-DXd as highly emetogenic and requires prophylactic antiemetics. It also instructs patients to report cough, dyspnea, fever, or other new respiratory symptoms immediately.
            • Screen Symptoms and Review CBC, Organ Function, and LVEF
              The label requires CBC before every dose, regular LVEF assessment as clinically indicated, and prompt investigation of respiratory symptoms. Organ function should be followed according to baseline impairment and clinical toxicity.
              • Identify the Management-Determining Toxicity
                • No Management-Determining Toxicity: Continue Treatment
                • Hold T-DXd and Obtain Chest CT and Pulmonary Evaluation
                  For suspected ILD, current labeling calls for treatment interruption, radiographic evaluation and consideration of pulmonology consultation.
                  • Classify Pulmonary Toxicity Grade and Etiology
                    Management depends on CTCAE grade and whether findings represent drug-induced ILD, radiation pneumonitis, infection, progression, or another cause.
                    • Grade 1 ILD: hold T-DXd, consider corticosteroids, and reimage
                      Grade 1 ILD: immediate management Asymptomatic radiographic ILD/pneumonitis suspected during T-DXd treatment. Hold T-DXd until complete resolution to Grade 0. Evaluate alternative causes, including infection, tumor progression and radiation-related lung injury. Review chest imaging and consider pulmonology consultation. Consider systemic corticosteroids promptly (e.g., prednisolone ≥0.5 mg/kg/day or equivalent), based on clinical assessment. Monitoring Monitor for new cough, dyspnea, fever or oxygen desaturation. Arrange clinical and radiographic reassessment to document resolution before restarting T-DXd. Individualize the timing of follow-up imaging according to clinical findings. T-DXd restart criteria Resolution to Grade 0 within ≤28 days of onset: resume at the same dose. Resolution to Grade 0 after >28 days: resume at one dose level lower. For breast cancer, the first dose reduction is from 5.4 to 4.4 mg/kg. Stop rule If symptomatic drug-induced ILD/pneumonitis (Grade ≥2) develops, permanently discontinue T-DXd and promptly initiate systemic corticosteroid treatment.
                      • Grade 1 ILD Recovered Promptly: Resume Same Dose
                      • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                        These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                    • Grade ≥2 Drug-Induced ILD: Permanently Discontinue T-DXd
                      This is a boxed-warning management requirement: permanently discontinue T-DXd and promptly initiate systemic corticosteroids for symptomatic Grade 2 or higher ILD.
                    • Grade 2 Radiation Pneumonitis: Hold; Resume Same Dose After Resolution
                      In the adjuvant HER2-positive breast cancer setting, distinguish radiotherapy-related pneumonitis from T-DXd–induced ILD. Evaluation: Review symptoms, oxygenation, chest CT findings, radiation fields, timing of radiotherapy, and alternative causes, including infection. Suspected T-DXd–induced ILD: For Grade 1, interrupt T-DXd until complete resolution and follow the ILD dose-modification pathway. For Grade 2 or higher, permanently discontinue T-DXd and promptly initiate corticosteroids. Only radiotherapy-related pneumonitis suspected: For Grade 2, consider interrupting T-DXd. For Grade 3 or higher, permanently discontinue T-DXd. Reassess clinical recovery and diagnosis before considering treatment resumption. This radiotherapy-specific exception applies only in the adjuvant setting.
                    • Grade ≥3 Radiation Pneumonitis: Permanently Discontinue T-DXd
                    • Treat Alternative Cause; Continue T-DXd Once ILD Is Excluded
                • Grade Neutropenia or Thrombocytopenia
                  Check CBC before each T-DXd dose and as clinically indicated. Grade 3 neutropenia (ANC 0.5 to less than 1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 4 neutropenia (ANC less than 0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Assess fever or suspected infection urgently and fFebrile neutropenia: ANC <1.0 x 10^9/L with temperature >38.3°C or ≥38°C sustained for more than 1 hour. Interrupt T-DXd. Urgently evaluate and treat suspected infection according to febrile neutropenia protocols. After resolution, resume T-DXd at one dose level lower. Do not re-escalate. Do not re-escalate T-DXd after dose reduction.
                  • Grade 3 Cytopenia: Hold Until Recovery; Resume Same Dose
                    Grade 3 neutropenia (ANC 0.5 to <1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 3 thrombocytopenia (platelets 25 to <50 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at the same dose. Check CBC and confirm hematologic recovery before the next infusion. Evaluate fever, infection, or clinically significant bleeding urgently.
                  • Grade 4 or Febrile Cytopenia: Hold; Resume at Reduced Dose
                    Grade 4 neutropenia (ANC <0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Febrile neutropenia (ANC <1.0 x 10^9/L with fever >38.3°C or ≥38°C sustained for more than 1 hour): Interrupt T-DXd. Urgently evaluate and treat infection according to institutional protocols. Resume at one dose level lower after resolution. Grade 4 thrombocytopenia (platelets <25 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at one dose level lower. Breast cancer dose levels: 5.4 → 4.4 → 3.2 mg/kg. Do not re-escalate after dose reduction.
                    • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                      These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                • Classify LVEF Change and Heart Failure Symptoms
                  The label stratifies management by absolute LVEF, change from baseline, confirmation on repeat testing and presence of symptomatic CHF.
                  • Mild LVEF Change: Continue T-DXd and Monitor
                    LVEF >45% with an absolute decline <10 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF >45% with an absolute decline of 10–20 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF 40–45% with an absolute decline <10 percentage points: Continue T-DXd and repeat LVEF within 3 weeks. Other LVEF declines or symptomatic heart failure: Follow the appropriate interruption or discontinuation pathway.Permanently discontinue T-DXd.
                  • Significant Asymptomatic Decline: Hold and Repeat LVEF
                    LVEF 40–45% with an absolute decrease of 10–20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF recovers to within 10% of baseline, resume T-DXd at the same dose. Otherwise, permanently discontinue. LVEF <40% or an absolute decrease >20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF <40% or the >20% decrease is confirmed, permanently discontinue T-DXd.
                    • LVEF Recovery Criteria Met: Continue Treatment
                      Following interruption for LVEF 40–45% with a 10–20% absolute decrease from baseline, resume T-DXd at the same dose only if LVEF recovers to within 10% of baseline. Continue regular LVEF monitoring and reassess any new cardiac symptoms. If recovery criteria are not met, permanently discontinue T-DXd.
                    • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                      Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                  • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                    Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                • Determine Outcome After Other Toxicity Management
                  • Controlled Other Toxicity: Continue or Resume Same Dose
                  • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                    These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                  • Severe Infusion Reaction: Permanently Discontinue T-DXd
        • HER2-Low/Ultralow Metastatic: T-DXd After Indicated Prior Therapy
          DESTINY-Breast04 supports previously chemotherapy-treated HER2-low disease, whereas DESTINY-Breast06 supports HR-positive HER2-low or ultralow disease after endocrine therapy and before metastatic chemotherapy.
          • Give Antiemetic Prophylaxis and Educate on Respiratory Symptoms
            Current labeling classifies T-DXd as highly emetogenic and requires prophylactic antiemetics. It also instructs patients to report cough, dyspnea, fever, or other new respiratory symptoms immediately.
            • Screen Symptoms and Review CBC, Organ Function, and LVEF
              The label requires CBC before every dose, regular LVEF assessment as clinically indicated, and prompt investigation of respiratory symptoms. Organ function should be followed according to baseline impairment and clinical toxicity.
              • Identify the Management-Determining Toxicity
                • No Management-Determining Toxicity: Continue Treatment
                • Hold T-DXd and Obtain Chest CT and Pulmonary Evaluation
                  For suspected ILD, current labeling calls for treatment interruption, radiographic evaluation and consideration of pulmonology consultation.
                  • Classify Pulmonary Toxicity Grade and Etiology
                    Management depends on CTCAE grade and whether findings represent drug-induced ILD, radiation pneumonitis, infection, progression, or another cause.
                    • Grade 1 ILD: hold T-DXd, consider corticosteroids, and reimage
                      Grade 1 ILD: immediate management Asymptomatic radiographic ILD/pneumonitis suspected during T-DXd treatment. Hold T-DXd until complete resolution to Grade 0. Evaluate alternative causes, including infection, tumor progression and radiation-related lung injury. Review chest imaging and consider pulmonology consultation. Consider systemic corticosteroids promptly (e.g., prednisolone ≥0.5 mg/kg/day or equivalent), based on clinical assessment. Monitoring Monitor for new cough, dyspnea, fever or oxygen desaturation. Arrange clinical and radiographic reassessment to document resolution before restarting T-DXd. Individualize the timing of follow-up imaging according to clinical findings. T-DXd restart criteria Resolution to Grade 0 within ≤28 days of onset: resume at the same dose. Resolution to Grade 0 after >28 days: resume at one dose level lower. For breast cancer, the first dose reduction is from 5.4 to 4.4 mg/kg. Stop rule If symptomatic drug-induced ILD/pneumonitis (Grade ≥2) develops, permanently discontinue T-DXd and promptly initiate systemic corticosteroid treatment.
                      • Grade 1 ILD Recovered Promptly: Resume Same Dose
                      • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                        These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                    • Grade ≥2 Drug-Induced ILD: Permanently Discontinue T-DXd
                      This is a boxed-warning management requirement: permanently discontinue T-DXd and promptly initiate systemic corticosteroids for symptomatic Grade 2 or higher ILD.
                    • Grade 2 Radiation Pneumonitis: Hold; Resume Same Dose After Resolution
                      In the adjuvant HER2-positive breast cancer setting, distinguish radiotherapy-related pneumonitis from T-DXd–induced ILD. Evaluation: Review symptoms, oxygenation, chest CT findings, radiation fields, timing of radiotherapy, and alternative causes, including infection. Suspected T-DXd–induced ILD: For Grade 1, interrupt T-DXd until complete resolution and follow the ILD dose-modification pathway. For Grade 2 or higher, permanently discontinue T-DXd and promptly initiate corticosteroids. Only radiotherapy-related pneumonitis suspected: For Grade 2, consider interrupting T-DXd. For Grade 3 or higher, permanently discontinue T-DXd. Reassess clinical recovery and diagnosis before considering treatment resumption. This radiotherapy-specific exception applies only in the adjuvant setting.
                    • Grade ≥3 Radiation Pneumonitis: Permanently Discontinue T-DXd
                    • Treat Alternative Cause; Continue T-DXd Once ILD Is Excluded
                • Grade Neutropenia or Thrombocytopenia
                  Check CBC before each T-DXd dose and as clinically indicated. Grade 3 neutropenia (ANC 0.5 to less than 1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 4 neutropenia (ANC less than 0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Assess fever or suspected infection urgently and fFebrile neutropenia: ANC <1.0 x 10^9/L with temperature >38.3°C or ≥38°C sustained for more than 1 hour. Interrupt T-DXd. Urgently evaluate and treat suspected infection according to febrile neutropenia protocols. After resolution, resume T-DXd at one dose level lower. Do not re-escalate. Do not re-escalate T-DXd after dose reduction.
                  • Grade 3 Cytopenia: Hold Until Recovery; Resume Same Dose
                    Grade 3 neutropenia (ANC 0.5 to <1.0 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at the same dose. Grade 3 thrombocytopenia (platelets 25 to <50 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at the same dose. Check CBC and confirm hematologic recovery before the next infusion. Evaluate fever, infection, or clinically significant bleeding urgently.
                  • Grade 4 or Febrile Cytopenia: Hold; Resume at Reduced Dose
                    Grade 4 neutropenia (ANC <0.5 x 10^9/L): Interrupt T-DXd until recovery to Grade 2 or lower, then resume at one dose level lower. Febrile neutropenia (ANC <1.0 x 10^9/L with fever >38.3°C or ≥38°C sustained for more than 1 hour): Interrupt T-DXd. Urgently evaluate and treat infection according to institutional protocols. Resume at one dose level lower after resolution. Grade 4 thrombocytopenia (platelets <25 x 10^9/L): Interrupt T-DXd until recovery to Grade 1 or lower, then resume at one dose level lower. Breast cancer dose levels: 5.4 → 4.4 → 3.2 mg/kg. Do not re-escalate after dose reduction.
                    • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                      These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                • Classify LVEF Change and Heart Failure Symptoms
                  The label stratifies management by absolute LVEF, change from baseline, confirmation on repeat testing and presence of symptomatic CHF.
                  • Mild LVEF Change: Continue T-DXd and Monitor
                    LVEF >45% with an absolute decline <10 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF >45% with an absolute decline of 10–20 percentage points: Continue T-DXd and routine LVEF monitoring. LVEF 40–45% with an absolute decline <10 percentage points: Continue T-DXd and repeat LVEF within 3 weeks. Other LVEF declines or symptomatic heart failure: Follow the appropriate interruption or discontinuation pathway.Permanently discontinue T-DXd.
                  • Significant Asymptomatic Decline: Hold and Repeat LVEF
                    LVEF 40–45% with an absolute decrease of 10–20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF recovers to within 10% of baseline, resume T-DXd at the same dose. Otherwise, permanently discontinue. LVEF <40% or an absolute decrease >20% from baseline: Interrupt T-DXd and repeat LVEF assessment within 3 weeks. If LVEF <40% or the >20% decrease is confirmed, permanently discontinue T-DXd.
                    • LVEF Recovery Criteria Met: Continue Treatment
                      Following interruption for LVEF 40–45% with a 10–20% absolute decrease from baseline, resume T-DXd at the same dose only if LVEF recovers to within 10% of baseline. Continue regular LVEF monitoring and reassess any new cardiac symptoms. If recovery criteria are not met, permanently discontinue T-DXd.
                    • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                      Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                  • Confirmed Severe Decline or Symptomatic CHF: Permanently Discontinue
                    Permanently discontinue T-DXd for: Confirmed LVEF <40% or an absolute decrease >20% from baseline. LVEF 40–45% with a 10–20% absolute decrease that does not recover to within 10% of baseline upon reassessment within 3 weeks. Symptomatic congestive heart failure, regardless of LVEF. Refer for cardiology or cardio-oncology evaluation and initiate appropriate heart failure management.
                • Determine Outcome After Other Toxicity Management
                  • Controlled Other Toxicity: Continue or Resume Same Dose
                  • Resume at Reduced Dose: Use 5.4→4.4→3.2 mg/kg; Never Re-Escalate
                    These are the FDA-labeled breast cancer dose-reduction levels. Treatment should be discontinued if a further reduction is required, and doses must not be re-escalated.
                  • Severe Infusion Reaction: Permanently Discontinue T-DXd
  2. T-DXd Dose Reduction Levels — Use When Indicated
    Use 5.4→4.4→3.2 mg/kg Dose Levels Never Re-Escalate
  3. Patient Handout
    Call your care team right away if you have: A new cough, or a cough that gets worse Shortness of breath or trouble breathing, at rest or with activity Fever (100.4°F (38°C) or higher, or the temperature your care team gave you) Also call if you have: Swollen legs or ankles, or trouble breathing when lying flat Nausea or vomiting that stops you from eating or drinking You might be pregnant, or your partner might be
tosprivacy